[1]李 菁,王 珏,朱悦琦,等.巴曲酶联合阿司匹林预防糖尿病下肢缺血病变介入术后再狭窄的疗效分析[J].介入放射学杂志,2014,(10):865-869.
 LI Jing,WANG Jue,ZHU Yue qi,et al.Application of batroxobin plus aspirin in preventing post intervention re stenosis in patients with diabetic lower limb ischemia: analysis of therapeutic effects[J].journal interventional radiology,2014,(10):865-869.
点击复制

巴曲酶联合阿司匹林预防糖尿病下肢缺血病变介入术后再狭窄的疗效分析 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2014年10期
页码:
865-869
栏目:
血管介入
出版日期:
2014-10-25

文章信息/Info

Title:
Application of batroxobin plus aspirin in preventing post intervention re stenosis in patients with diabetic lower limb ischemia: analysis of therapeutic effects
作者:
李 菁 王 珏 朱悦琦 张培蕾
Author(s):
LI Jing WANG Jue ZHU Yue qi ZHANG Pei lei.
Department of Diagnostic and Interventional Radiology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai 200233, China
关键词:
【关键词】 巴曲酶 阿司匹林 血管成形术 再狭窄
文献标志码:
A
摘要:
【摘要】 目的 探讨巴曲酶联合阿司匹林预防糖尿病下肢缺血病变介入术后再狭窄的疗效。方法110例症状性血管闭塞的糖尿病患者随机分为实验组50例和对照组60例。实验组患者接受阿司匹林(100 mg/d)联合巴曲酶治疗(5 u/d × 6次,隔天应用),对照组单独应用阿司匹林。以12个月为随访终点,通过下肢磁共振血管成像(MRA)或者血管超声来评估血管再狭窄或者再闭塞的情况。统计踝以上截肢、死亡人数,以及截肢或死亡累积发生率,运用Kaplan Meier生存曲线来评估保肢率和存活率。结果 12个月后,实验组再狭窄发生率为28.9%,对照组为42.8%(P = 0.002)。MRA及血管超声显示膝下动脉(P =0.003)和长度 > 10 cm(P = 0.001)再狭窄发生率高。Kaplan Meier生存曲线显示血管成形术12个月后,对照组和实验组保肢/存活率分别为78.2%和93.5%(log rank检验,P = 0.032 4)。结论 巴曲酶联合阿司匹林可以有效减少血管成形术后再狭窄发生率,尤其针对膝下病变 > 10 cm者,有着更好的临床疗效,并且可以提高患者的肢体挽救率。

参考文献/References:

[1] Schillinger M, Exner M, Mlekusch W, et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis[J]. Radiology, 2002, 225: 21 26.
[2] J?覿msén T, Manninen H, Tulla H, et al. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia[J]. J Vasc Interv Radiol, 2002, 13: 455 463.
[3] Wang J, Zhu YQ, Zhao JG, et al. Infrapopliteal angioplasty with a long over the wire (OTW) balloon in the treatment of severe limb ischemia in diabetic patients: a retrospective study[J]. Acta Radiol, 2009, 50: 360 367.
[4] Zhu YQ, Zhao JG, Liu F, et al. Subintimal angioplasty for below the ankle arterial occlusions in diabetic patients with chronic critical limb ischemia[J]. J Endovasc Ther, 2009, 16: 604 612.
[5] Mannava K, Money SR. Current management of peripheral arterial occlusive disease: a review of pharmacologic agents and other interventions[J]. Am J Cardiovasc Drugs, 2007, 7: 59 66.
[6] 王 燕, 段 峰, 李志伟, 等. 预防血管内支架植入术后再狭窄的研究进展[J]. 介入放射学杂志, 2011, 20: 665 668.
[7] Antithrombotic Trialists’ Collaboration. Collaborative meta analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. Br Med J 2002; 12; 324: 71–86.
[8] Alvarez Perez FJ, Castelo Branco M, Alvarez Sabin J. Usefulness of measurement of fibrinogen, D dimer, D dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke[J]. J Neurol Neurosurg Psychiatry, 2011, 82: 986 992.
[9] 韩 健, 郭富强. 经皮腔内血管成形术后再狭窄的炎症预测因子[J]. 介入放射学杂志, 2009, 18: 876 879.
[10] De Moerloose P, Boehlen F, Neerman Arbez M. Fibrinogen and the risk of thrombosis[J]. Semin Thromb Hemost, 2010, 36: 7 17.
[11] Schillinger M, Exner M, Mlekusch W, et al. Fibrinogen predicts restenosis after endovascular treatment of the iliac arteries[J]. Thromb Haemost, 2002, 87: 959 965.
[12] Sacks D, Marinelli DL, Martin LG, et al. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices[J]. J Vasc Interv Radiol, 2003, 14: S395 S404.
[13] Germano G, Hobbs R, Hoes A, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)[J]. Eur Heart J, 2012; 33: 1635 1701.
[14] Ishii H, Kumada Y, Toriyama T, et al. Cilostazol improves long term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease[J]. Clin J Am Soc Nephrol, 2008, 3: 1034 1040.
[15] Serrano SM. The long road of research on snake venom serine proteinases[J]. Toxicon, 2013, 62: 19 26.
[16] Xu G, Liu X, Zhu W, et al. Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention[J]. Blood Coagul Fibrinolysis, 2007, 18: 193 197.
[17] Wilensky RL, March KL, Gradus Pizlo I, et al. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit[J]. Circulation, 1995, 92: 2995 3005.
[18] 薛 波, 张培蕾, 王 珏, 等. 巴曲酶预防糖尿病膝下血管病变介入成形术后再狭窄的前瞻性随机对照研究[J]. 介入放射学杂志, 2011, 20: 202 206.

相似文献/References:

[1]张彩珍,田巧莲,苏秀琴,等.介入放射治疗中病人的护理[J].介入放射学杂志,1999,(02):54.
[2]金惠根,李京波,陆志刚,等.冠脉支架内血栓形成致急性心肌梗死[J].介入放射学杂志,2000,(01):27.
[3]金惠根,陆志刚,顾水明,等.直接冠脉内支架术治疗冠脉狭窄[J].介入放射学杂志,2000,(02):109.

备注/Memo

备注/Memo:
(收稿日期:2014-03-20)
(本文编辑:李 欣)
更新日期/Last Update: 2014-10-21